Yeda Research and Develpment & Co. Ltd

Yosef Yarden

Michael Sela

Bilha Schechter

Daniel Harari

Moshit Lindzen

Nadège Gaborit

Ruth Maron

Tsipi Ben-Kasus

Silvia Carvalho

Maicol Mancini

Georg Mahlknecht

Pradeep Chaluvally-Raghavan

A method of determining the suitability of a subject to a treatment with an anti-amphiregulin antibody, wherein the subject has a cancer selected from the group consisting of ovarian cancer, head and neck cancer and pancreatic cancer exhibiting resistance to chemotherapy, is provided. The method comprising analyzing in a biological sample of the subject expression level of amphiregulin, transforming growth factor alpha (TGF-alpha) and heparin-binding epidermal growth factor (HB-EGF), wherein a level of expression of the amphiregulin above a predetermined threshold and no expression of the TGF-alpha and/or the HB-EGF or an expression below a predetermined level of the TGF-alpha and/or the HB-EGF is indicative of the suitability of the subject to treatment with the anti-amphiregulin antibody. Methods for treating cancer are also provided, as well as antibodies and pharmaceutical compositions.

Anti amphiregulin antibodies, compositions comprising same and uses thereof

An isolated polypeptide is provided. The isolated polypeptide comprising an antigen recognition domain specifically binding human HER-3 with a Kvalue of 10 nM or lower, wherein the polypeptide inhibits neuregulin (NRG) binding to the human HER3 and NRG-induced cancer cell migration and proliferation. Additionally clones NG83 and NG140 are provided which bind human HER-3 with a Kvalue of 10 nM or lower.

Anti-HER3 antibodies and uses of same

Methods of treating a subject having cancer exhibiting a resistance to a tyrosine kinase inhibitor (TKI) are provided. Accordingly, there is provided a method comprising administering to the subject a therapeutically effective amount of antibodies comprising an anti-EGFR antibody, an anti-HER2 antibody and an anti-HER3 antibody. Also provided are compositions and articles of manufacture for treating cancer resistance to a TKI. Also provided are methods of treating non-resistant tumors.

Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (TKI)

Monomeric and multimeric aptamers are provided. Also provided are pharmaceutical compositions which comprise same and methods of using same.

Aptamers, multimeric aptamers and uses thereof

A method of selecting a target for treatment of a hyperproliferative disease in a subject in need thereof is disclosed. The method comprising analyzing an amount and/or activity of at least one ErbB ligand in a biological sample from the subject, wherein an ErbB ligand which shows an up-regulated amount and/or activity compared to a non-hyperproliferative cell or tissue above a predetermined level is selected as a target for treatment of the hyperproliferative disease. Methods of treating hyperproliferative diseases, monoclonal antibodies and pharmaceutical compositions are also disclosed.

Antibodies and methods of using same for treating ErbB/ErbB ligands associated diseases

A method of treating a ductal carcinoma in situ (DCIS) lesion in a subject in need thereof is disclosed. The method comprises administering to the subject a therapeutically effective amount of a first agent capable of down-regulating activity and/or expression of at least one component participating in a NOTCH pathway, and a second agent capable of down-regulating an activity and/or expression of HER2, thereby treating the DCIS lesion.

Combination therapy to prevent DCIS formation and progression to breast cancer

A method of identifying a combination of antibodies with a combined improved anti-tumor activity is provided. The method comprising: (a) identifying binding epitopes of anti ErbB-2 antibodies; and (b) selecting a combination of at least two antibodies of the anti ErbB-2 antibodies exhibiting binding to different epitopes on the ErbB-2, at least one of the different epitopes being localized to a dimerization site of the ErbB-2, the combination of antibodies being with the combined improved anti-tumor activity. Also provided are novel antibody combinations uncovered according to the present teachings.

Antibody combinations and use of same for treating cancer

An article-of-manufacture is provided. The article-of-manufacture comprises a packaging material identified for treating cancer, packaging: Also provided are pharmaceutical compositions and methods of using the above antibodies as well as other antibody combinations for the treatment of cancer.

Combinations of anti ErbB antibodies for the treatment of cancer

The present invention provides for isolated polypeptides capable of binding ErbB-4.

Growth factor which acts through ErbB-4 RTK

A method of identifying a combination of antibodies with a combined improved anti tumor activity is provided. The method comprising identifying at least two anti RTK antibodies capable of inducing synergistic endocytosis of the RTK in a cell expressing the RTK, thereby identifying the combination of antibodies with the combined improved anti-tumor activity.

Anti-EGFR antibodies with an improved anti-tumor activity and compositions and articles of manufacture comprising same

Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies

A novel ErbB-4 ligand, referred to herein as Neuregulin-4 (NRG-4) is disclosed as well as polynucleotide sequences encoding NRG-4, oligonucleotides and oligonucleotide analogs derived from polynucleotide sequences, a display library displaying short peptides derived from NRG-4, antibodies recognizing NRG-4, peptides or peptide analogs derived from NRG-4, and pharmaceutical compositions and methods of employing peptides or peptide analogs, oligonucleotides and oligonucleotide analogs, and/or polynucleotide sequences to up-regulate or down-regulate ErbB-4 receptor activity (signaling).

Growing community of inventors

Rehovot, Israel

Yosef Yarden